TELOCYTE
A FUTURE BEYOND ALZHEIMER'S

Welcome to the Telocyte Newsletter. Our goal is to keep you up to date on the **company, industry, and science. Our primary drive is to cure Alzheimer's disease** using paradigm shifting science and technology. For those who want to get a great overview of the **science please read Dr. Michael Fossel's latest book, The** Telomerase Revolution. This book provides a clear explanation of how aging and age-related diseases work, and why we believe that we can now intervene in a novel and far more effective way.

Look for this newsletter quarterly; this is the Q4 2016 edition. If you have not been to our website, please visit it and read about our great management team, our collaborators, and our scientific and medical advisors. In future newsletters, the team will offer insight about the business and the science. We encourage you to share this with your friends, family, and colleagues. Feel free to ask us questions **via the website regarding this or future newsletters. If for any reason you'd prefer** not to receive this quarterly newsletter, let us know by simply using the **"unsubscribe" link below.**

What are we doing at Telocyte?

Our mission is simple: we intend to cure Alzheimer's disease.

As many of you know by now, we are confident that, given what we know about aging and disease, we can both prevent and cure Alzheimer's disease, demonstrating it in FDA trials within the next two years. This is an extraordinary

goal, particularly given the uniform failure of every other FDA-tested intervention. All other pharmaceutical firms and biotechnology companies are hoping they can find a way to slow the course of the disease. Their fatalism leads them to hoping that they can diagnose Alzheimer's before it's even apparent clinically, hoping they can intervene "before the pathology occurs." None of them – not a one – believes that they can reverse the pathology.

Nevertheless, our aim is precisely that. We have good reasons – based on both theory and experimental data – to believe that Alzheimer's begins with age-related changes in our glial cells, the cells that take care of our neurons. Moreover, we know that we can reverse those age-related changes, permitting glial cells to function normally and to take care of our neurons. Luckily, while some neural damage may be beyond repair, much of the damage that occurs in the neurons is reversible. We intend to do exactly that: reset glial cell function, reverse the damage in neurons, and reverse much of the cognitive decline seen in Alzheimer's disease.

In short, we intend to provide not Band-Aids, not symptomatic care, not an expensive drug that might provide a few more months in a nursing home, but a cure. We don't want people to learn how to "live with Alzheimer's", we want people to live without it.

Where are we going at Telocyte?

We need two things: investments and our FDA trials.

In order to do our FDA phase 1 human trial, we need to finish our animal study for the FDA. The animal study will take about 6 months; the human study will take another 6 months. To do both of these will take about five million dollars.

At the moment, we have a significant percentage of that already, and we are currently negotiating with several venture capital firms who like what we're trying to do. We expect to negotiate with them over the next few months, then move ahead with our work.

The first step, the animal study, is needed for the FDA to grant us permission to do the human study. They are mostly concerned not with efficacy, but with safety. Most of our animal protocol, therefore looks at side effects and complications, both in mice and in human cells in the laboratory. So far, we know that our therapy, if anything, makes the mice (and cells) healthier, but we have to demonstrate that in perhaps a hundred animals.

The second step, the initial human trial, generally aims at safety, but we expect to see clinical improvement, even in our small, initial trial. Showing such a result in an Alzheimer's trial would be unprecedented, but will allow us to move faster as we transition from the laboratory to the clinic. Our initial trial will be about a dozen patients. Oddly enough, while all other pharmaceutical firms and biotechnology companies enroll only patients with early Alzheimer's – not believing they can improve the disease and hoping they can slow it – we will be enrolling patients with moderate Alzheimer's.

There are two reasons for this. First, we can't very well improve a patient unless they already have significant problems to improve. You can't fix what isn't broken. Second, we want to be sure that everyone agrees that our patients initial have Alzheimer's. We know that if we show we can reverse the cognitive decline in patients who only started with minimal disease, most people "knowing" you can't cure Alzheimer's, will assume the diagnosis was wrong. In short, when we show people we can fix it, most people will assume it wasn't really broken. So we will treat patients that, without any possible doubt, have significant Alzheimer's.

With luck, our animal trials will begin in the next few months and our human trials a year later.

Thank you for joining us in our endeavor: we want to cure Alzheimer's dementia within the next 2-3 years. Our aim is to ensure that none of us ever have to "live with Alzheimer's". We would rather that all of us live without it.
Now let's make it happen.

Dr. Micheal Fossel, Founder and President of Telocyte.